The Synergistic Potential of Cannabis Sativa L. Phytochemicals on Angiotensin-Converting Enzyme (ACE)

January 29, 2024 @ 12:15 pm to 01:15 pm

Francisco Chacon, Penn State University

108 Wartik Laboratory
University Park

Abstract:
The pharmacological activity of Cannabis sativa L., or hemp, is largely attributed to the plant’s secondary metabolites, particularly C21 terpeno-phenolic compounds (the “cannabinoids”); however, the mechanistic effects/interactions of cannabinoids on blood pressure regulation have yet to be described. This study aims to explore the diversity of cannabis compounds and their effects on angiotensin-converting enzyme (ACE) activity, an essential component of a major blood pressure regulating system. Using in vitro, in silico, and mass spectrometry practices this investigation details the isolated effects cannabinoids have on ACE activity in human cells and evidence of potential synergism cannabis compounds may have on common target for hypertensive treatment, offering pertinent information on an under studied topic surrounding the health and safety of hemp compounds.

About the Speaker:
Cisco Chacon is a 4th year Ph.D. candidate in Dr. Josh Kellogg’s group. He joined the Plant Biology Graduate Program at Penn State in 2020, after obtaining his B.S. in Genetics and Biotechnology from New Mexico State University. His interest lies in the chemistry of medicinally active plants and the advancements of techniques and instrumentation in mass spectrometry. Cisco’s work explores the effects cannabinoids and terpenes from Cannabis sativa L. have on systems that help regulate blood pressure.

Contact

Joshua Kellogg
jjk6146@psu.edu